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The structure of novel binary nanosponges consisting of (cholesterol-(K/D)nDEVDGC)3-trimaleimide units
possessing a trigonal maleimide linker, to which either lysine (K)20 or aspartic acid (D)20 are tethered, has
been elucidated by means of TEM. A high degree of agreement between these ﬁndings and structure
predictions through explicit solvent and then coarse-grained molecular dynamics (MD) simulations has
been found. Based on the nanosponges' structure and dynamics, caspase-6 mediated release of the
model drug 5(6)-carboxyﬂuorescein has been demonstrated. Furthermore, the binary (DK20)
nanosponges have been found to be virtually non-toxic in cultures of neural progenitor cells. It is of
a special importance for the future development of cell-based therapies that DK20 nanosponges were
taken up eﬃciently by leucocytes (WBC) in peripheral blood within 3 h of exposure. The percentage of
live cells among the WBC was not signiﬁcantly decreased by the DK20 nanosponges. In contrast to stem
cell or leucocyte cell cultures, which have to be matched to the patient, autologous cells are optimal for
cell-mediated therapy. Therefore, the nanosponges hold great promise for eﬀective cell-based tumor
targeting.Introduction
One of the grand challenges in nanomedicine is the eﬀective
targeting of tumors and metastases.1 For almost a generation,
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0exosomes,6 nanoparticles,7 polymer-based nanostructures8–10)
through gaps in the vasculature that have been built rapidly
around tumor tissue, has been hailed as an important break-
through in the ght against cancer. Unfortunately, emerging
evidence clearly suggests that the EPR eﬀect works well in rodent
models (especially in nudemice), but not in humans, who feature
distinctly diﬀerent vasculature and, compared to rodents,
signicantly slower tumor growth.2,3,11 Therefore, alternative tar-
geting approaches are urgently needed. Active targeting strategies
use either antibodies,12–14 antibody-fragments,15–17 peptide
sequences15,16,18 or aptamers,15,16 which are capable of targeting
receptors that are overexpressed in solid tumors, as for instance
members of the integrin family.19,20 However, active targeting
processes can be impaired by physiological barriers, such as high
interstitial uid pressures and the formidable physical barrier
imposed by tumor stroma.21 Therefore, cell-mediated transport
of anticancer drugs into the tumor tissue is, in the opinion of the
authors, the most viable strategy to develop intelligent alterna-
tives to chemotherapy.10,22–27 Transport cells have the ability to
migrate to tumors andmetastases following cytokine/chemokine
gradients.28 Among them are stem cells,29 monocytes/macro-
phages30,31 and neutrophils.32,33 Neural stem cells, which can be,
principally, cultured and matched to patient-types, have been
successfully utilized for cell-mediated therapies in rodent
models,22,27,34 as well as neutrophils35,36 and monocytes.10,23,24,27This journal is © The Royal Society of Chemistry 2018
Scheme 1 Principles of cell therapy utilizing nanosponges. Neutro-
phils in peripheral blood will be loaded by targeting them with peptide
nanosponges. After the blood has been given back intravenously to the
patient, it is anticipated that the neutrophils will home to tumors within
6–12 h. Alternatively, neural stem cells can be cultured, loaded with
peptide nanosponges and injected intravenously into the patient.
Fig. 1 Typical structure of a nanosponge according to coarse grained
molecular dynamics simulations, which are described in detail in ref.
38. Red: aspartate groups, blue: lysine groups, cyan: cholesterol
aggregates, green: peptide backbone.
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View Article OnlineThe use of autologous cells has the potential of developing truly
patient specic therapies, and also of signicantly lowering the
regulatory barriers for cell-based human cancer therapies.37
Targeting neutrophils and monocytes in peripheral blood will
avoid the necessity for their time-consuming isolation and
culturing, and further reduce the regulatory hurdles since cell
isolation is not necessary. In Scheme 1, the principles of cell-
based cancer therapy are shown. In step 1, the selected trans-
port cell type is targeted. In order to maintain high transport cell
viabilities, carrier particle (vector) recognition and uptake by the
transport cell(s) has to be very eﬃcient. Furthermore, the vectorFig. 2 Tri-maleimide based peptide structures: components for the s
component K20 (MW ¼ 11 334.74 g mol1); (B) aspartic acid-based com
This journal is © The Royal Society of Chemistry 2018that is used to facilitate uptake has to be virtually non-toxic. Aer
the cells have been returned to the host, they actively migrate to
tumors and metastases following cytokine/chemokine gradients.
The last step consists in the triggered release of the payload and
uptake of the latter by the tumor and stromal cells.27
This team has recently reported the design, synthesis, and
characterization of designer peptide-nanosponges for eﬃcient
uptake by delivery cells in drug delivery.38 Their supramolecular
building blocks consist of (cholesterol-(K/D)nDEVDGC)3-trima-
leimide units featuring a trigonal maleimide linker to which
either lysine (K)20 or aspartic acid (D)20 are attached. Further-
more, a consensus sequence for caspase-6 (DEVD-GC)39 is
integrated into the structures. This consensus sequence can
also be activated by other executioner caspases, such as caspase-
3, and -7. There is emerging evidence that caspases can actively
contribute to the development and progression of tumors.40
This is in agreement with clinical evidence for the presence of
active caspases in tumors.40 Caspases 3 and 6 are taken up
by cells and are, therefore, suitable to cleave the consensus
sequences of nanosponges that have been taken up by transport
cells, thus triggering their release by means of apoptotic
processes, which enhance the porosity of the transport cells and
then dissect them into apoptotic bodies.41 Both, (cholesterol-
(K)20DEVDGC)3-trimaleimide and mixtures of (cholesterol-
(K)20DEVDGC)3-trimaleimide and (cholesterol-(D)20DEVDGC)3-
trimaleimides form stable nanosponges (short notation: DK20).
The structure of the novel nanosponges was investigated
through explicit solvent and then coarse-grained molecular
dynamics (MD) simulations. As Fig. 1 indicates, the nano-
sponge structure is featuring aspartate- and lysine-rich regions,
together with cholesterol domains and (aqueous) solvent lled
nanoholes. The resulting structure is uctuating, depending on
the temperature. Upon mixing with aqueous buﬀers DK20,
nanosponges are immediately formed. They possess very low
polydispersities and are long-term stable (up to 72 h as experi-
mentally determined). They are capable of incorporating uo-
rescent dyes (e.g. carboxyuorescein (discussed here) or PKH26
(ref. 38)), which can be used for uorescence imaging and
payload release studies.
It is noteworthy that the Coarse Grained MD Simulations did
not result in spherical nanosponges due to the limited numberpontaneous formation of type DK20 nanosponges. (A) Lysine-based
ponent D (MW ¼ 10 439.51 mol1).
RSC Adv., 2018, 8, 16052–16060 | 16053
Fig. 3 (A) TEM image of type DK20 nanosponges on HOPG, as
deposited from PBS solution. Bright ﬁeld transmission TEM (200 kV) of
a type DK20 nanosponge. Water-ﬁlled vesicles are discernible as dark
spots within the bright nanosponge. (B) Same image as in 3A after
black/white correction ﬁlter function in Photoshop.
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View Article Onlineof small trigonal units in these simulations. However, as shown
below in Fig. 3, the principal ndings from these simulations
were corroborated by means of TEM.
In order to function properly, the nanosponges should be
taken up quickly by the transport cells, transported to the tumor
sites, and then released. The latter will be achieved by means of
programmed cell death (apoptosis), which will occur naturally
in neutrophils 12 to 24 h aer reaching the tumor environ-
ment,42 or bymeans of triggered apoptosis (other leucocytes and
neural stem cells27). Caspase activation is the hallmark of
apoptosis.43 We will utilize caspases, which are proteolytic
enzymes, to activate the nanosponges for drug delivery
purposes.
In this report, we will describe rened structural investiga-
tions by TEM, in vitro release studies of the model drug car-
boxyuorescein by caspase-6 activation, as well as cell targeting
experiments of cultured neural stem cells and leucocytes in
peripheral (bovine) blood. The data obtained from these
experiments will demonstrate the unique properties of type
DK20 nanosponges.
Experimental
Synthesis and characterization of the nanosponges
The synthesis of all building blocks required for the assembly of
DK20 and K20 nanosponges, as well as their characterization by
NMR and MALDI-TOF has been described in an earlier report
(Fig. 2).38
TEM characterization
Samples for transmission electron microscopy (TEM) were
prepared by dropping 10 mL of 0.050 mM type DK20 solution in
PBS directly on a glow discharged TEM grid. Uranyl acetate was
used as a positive staining agent in all TEM experiments. In all
cases electron microscopy was performed at an accelerating
voltage of 200 kV. Nanosponge morphology on HOPG was
examined by bright-eld and dark-eld transmission electron
microscopy (TEM) using a FEI Technai G2 transmission electron16054 | RSC Adv., 2018, 8, 16052–16060microscope at an electron acceleration voltage of 200 kV. Dark-
eld TEM did not reveal a characteristic diﬀraction pattern.
High resolution images were captured using a standardized,
normative electron dose and a constant defocus value from the
carbon-coated surfaces. All TEMmeasurements were performed
at the Microscopy and Analytical Imaging Laboratory of the
University of Kansas.44Nanosponge formation and DLS characterization
The hydrodynamic diameter and polydispersity index (PDI) of
the formed nanosponges were measured by dynamic light
scattering (DLS, ZetaPALS, Brookhaven Instruments Corp.,
Holtsville, NY). All measurements were carried out at 25 C, with
658 nm laser wavelength, and 90 degree detection angle. Data
were collected from an average of three measurements over 60
seconds.Carboxyuorescein encapsulation
Equal molar ratios of (cholesterol-(K)20DEVDGC)3-trimaleimide
and (cholesterol-(D)20DEVDGC)3-trimaleimide (5.0  104 M of
each component) were dissolved in 10 mM carboxyuorescein
PBS (pH ¼ 7.4) solution. Aer incubating at room temperature
for 2 hours, the solution was transferred to a 3500 Da molecular
weight cutoﬀ dialysis bag. Free carboxy-uorescein was
removed by means of continuous dialysis against 1  PBS
buﬀer until virtually no uorescence could be detected in the
solution using a Fluoromax-2 spectrometer. Using a uores-
cence calibration curve, it was estimated that the concentration
of free carboxyuorescein was < 1 nM. At this point, a dark red
color was still retained inside the dialysis bag. This nding
provided a good indication that carboxyuorescein had been
trapped inside the peptide nanosponges. From the integrated
UV/Vis-absorption of the dialysis solution we have estimated
that 65 4 mol% of carboxyuorescein was encapsulated in the
procedure. Aer lyophilizing to dryness, a yellow/brown powder
was obtained, which could be easily re-dispersed in PBS by
vortexing for 5 min. In a subsequent dialysis experiment, it was
found that virtually no carboxyuorescein was leached aer 24,
48, and 72 h. The UV/Vis and uorescence spectra of carboxy-
uorescein, as well as the uorescence calibration curve as
a function of carboxyuorescein concentration can be found in
the ESI section (Fig. S1, S2, and S3†). The average number of
encapsulated carboxyuorescein molecules per DK20 nano-
sponge was estimated to 8.5  2.Caspase-6 triggered dye release
The dye release experiment was performed using a uorescence
plate reader (BioTek Synergy H1). 200 mL of carboxyuorescein
loaded nanosponges in PBS solution (0.20 mg mL1) were
added to each well of a 96-well black clear-bottom plate. To each
control well, 10 mL of PBS buﬀer was added, and to each
experimental well, 10 mL of caspase-6 PBS solution (0.1 mgmL1,
2.2  107 M, Enzo LifeSciences) was added.
The plate was incubated at 37 C, the uorescence intensity
at 520 nm was recorded every 5 min.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineCell experiments and MTT assays
The cytotoxicity of the PKH26 containing nanosponges was
assessed by utilizing the MTT assay45 on C17.2 neural progen-
itor cells (NPCs),34 which were a gi from Dr. V. Ourednik (Iowa
State University) to Dr. D. L. Troyer, DVM (Kansas State
University, Anatomy & Physiology). NPCs were originally devel-
oped by Dr. Evan Snyder.46 These cells were maintained in
DMEM supplemented with 10% FBS (Sigma-Aldrich), 5% horse
serum (Invitrogen), 1% glutamine (Invitrogen), and 1%
penicillin/streptomycin (Invitrogen). PKH26 is a hydrophobi-
cally modied cyanine 3.0 dye. The preparation of PHK26-
loaded type DK20 nanosponges was described earlier.38 Cell
experiments were carried out in the culturing medium
described above. The percentage of viable cells was determined
aer 24 and 48 hours of incubation. Cells were seeded in T-25
ask. Aer 24 h of incubation at 37 C, cells were re-plated in
a 96 well plate at 20 000 cm2 density and further incubated for
24 h at 37 C to obtain 80% conuency before the nanosponges
were added.
Concentration series of type DK20 nanosponges (0.0, 0.1, 0.2,
0.5, 1.0, 2.0, 5.0, 10, 20, 40, 60, 80, 100 mmol L1 in total, molar
ratio 1 : 1) were prepared by dissolving the nanosponge
components in the same media that were used for culturing the
cells. Cells were incubated for 24/48 h at 37 C. Eight replicates
were prepared for each concentration. A portion of 10 mL of MTT
reagent (5 mg mL1 in PBS) was added to each well, and the
plates were incubated for another 4 h at 37 C. Finally, 100 mL of
10% sodium dodecyl sulfate in 0.010 M HCl was added into
each well and incubated for 24 h at 37 C. Their absorbance was
recorded by using a plate reader at 550 nm and 690 nm. PBS
solution was used as control for all the experiments.
Murine stem cells were imaged by using a Zeiss, Axiovert 40
CFL microscope with darkeld, brighteld, phase contrast and
epiuorescence illumination, a camera system and Jenoptik,
ProgRes C3 Cool camera and a ProgRes Capture Pro 2.10.0.0
soware.Fig. 4 Caspase-6 triggered carboxyﬂuorescein (CF) release. Type
DK20 nanosponges containing carboxyﬂuorescein (0.0005 M of D20
and K20, see ESI†) were incubated with PBS (control, green dots), as
well as 1.0  108 M caspase-6 in PBS (blue triangles), 1.0  107 M
caspase-6 in PBS (purple diamonds), and 1.0  106 M caspase-6 in
PBS (red squares) at 37 C (pH ¼ 7.4). (A) The observed ﬂuorescence
emission intensity (relative units) occurring from carboxyﬂuorescein
was recorded at 513 nm with a 5 nm bandpass ﬁlter, lexc ¼ 493 nm, as
a function of time. (B) Hydrodynamic diameters (measured by means
of DLS) vs. time. Experimental errors are shown for all cases where they
extend beyond the size of the symbols.Cell uptake from peripheral blood
Bovine blood was obtained at the Kansas state feed lot. Blood
was collected in citrated (0.105 M) 4.5 ml tubes (BD Vacutainer,
Franklin Lakes, NJ, USA). The collected blood was pooled and
split into 3.0 ml samples. Samples were supplemented with
1.0 mL of serum free RPMI medium to ensure supply of nutri-
ents. The samples were incubated with 1.0 mL of 1.0 mg mL1
type DK20 nanosponges in PBS at 37 C. Leukocytes (WBC) were
extracted via removal of the buﬀy coat aer centrifugation.47,48
Red Blood Cell Lysis Buﬀer (Sigma-Aldrich, St. Louis, MO, USA)
was used to remove any remaining red blood cells and the
samples were washed with PBS (10 min, 500 g). Cells were
counted via hemocytometer and diluted to achieve a concen-
tration of 5  105 cells per mL, suitable for analysis by ow
cytometry (Guava EasyCyte, EMD Millipore). The survival of
WBC incubated type DK20 nanosponges was detected with
a annexin V/propidium iodine apoptosis kit (Novus Biologicals).
The protocol provided with the kit was exactly followed.This journal is © The Royal Society of Chemistry 2018Results
TEM-analysis of the nanosponge structure
Bright eld transmission electron microscopy was able to reveal
structures that are formed aer depositing the nanosponges
directly onto HOPG grids and exposing them to the high
vacuum inside the TEM. The attened nanosponges contain
dark spots, which are indicatives of water/buﬀer-lled pockets
inside the structure. Furthermore, aer applying a black/white
correction lter function available in Adobe Photoshop,
brighter than average spots can be discerned within the nano-
sponge structure, which are indicative of cholesterol-rich
regions. The average grey within the structure shown on
Fig. 3B suggests the presence of both, lysine and aspartate-rich
regions, which retain some of their water-content in high
vacuum. These ndings are in excellent agreement with the
principal results of themolecular dynamics (MD) simulations of
nanosponge structure.
It is noteworthy that the nanosponges, obtained under the
experimental conditions described here, appear to be larger
(240  30 nm in diameter), whereas their diameter reportedRSC Adv., 2018, 8, 16052–16060 | 16055
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View Article Onlineearlier was 90  15 nm.38 However, a DK20 concentration
approx. Five times lower (than reported in ref. 38).Caspase-6 triggered carboxyuorescein release
Carboxyuorescein is a uorescent dye, which has been used for
microscopy and cell-tracking purposes. It is established that at
increased concentrations, carboxyuorescein undergoes
intense self-quenching.9,49 A detailed investigation of the
concentration-dependent quenching of carboxyuorescein in
liposomes revealed both, monomer–monomer and monomer–
dimer energy transfer processes.50 Carboxyuorescein dimers
are non-uorescent. Because carboxyuorescein uorescence
can increase as a function of decreasing dye concentration, it
has become a popular probe detecting drug release from
a delivery system.9,51,52 Aer entrapping carboxyuorescein into
type DK20 peptide nanosponges and subsequent lyophilizing to
a powder, the obtained solid was dissolved in 3.0 mL PBS buﬀer
(pH ¼ 7.4). DLS measurements showed that the hydrodynamic
diameter was 213  25 nm before adding caspase-6 (see
Fig. S4†). The nanosponges remained stable in PBS over a 24 h
period. Dye release experiments using three concentrations of
capase-6 are shown in Fig. 4A, together with the hydrodynamic
diameters of the nanosponges, observed by means of DLS
(Fig. 4B). The hydrodynamic diameters of the nanosponges
steadily increased in the presence of caspase 6, indicating
cleavage of the caspase-6 cleavage site DEVDGC,39 and subse-
quent formation of new micro-sized structures. At all three
investigated concentrations of caspase-6, a maximum hydro-
dynamic diameter of 1300  50 nm was detected my means of
DLS, albeit at diﬀerent reaction times. The observed uores-
cence intensities of carboxyuorescein were clearly a function of
the added caspase-6 concentration. When 1.0  108 M of
caspase-6 was added, the uorescence intensity decreased
during the rst 25 min., which was followed by an increase.
Aer 35 min. A plateau was reached, which corresponded to an
overall uorescence increase of 3.7  0.1%. When 1.0  107 M
of caspase-6 was added, the observed decrease in uorescence
was smaller, and a plateau corresponding to an overall uo-
rescence increase of 24.4  0.5% was reached aer 55 min.
When 1.0  106 M of caspase-6 was added, the observedFig. 5 Bright ﬁeld transmission TEM (200 kV) of 0.20 mg mL1 of
carboxy-ﬂuorescein-loaded CF-DK20 nanosponges: (A) Nano-
sponges deposited from PBS before adding caspase-6. (B) Reactive
mixture deposited from PBS containing caspase-6 (2.60  1010 M)
after 15 min of reaction at 37 C. (C) Novel nanostructures, which were
formed in the reaction, deposited from PBS containing caspase-6
(2.60  1010 M) after 60 min of reaction at 37 C.
16056 | RSC Adv., 2018, 8, 16052–16060decrease in uorescence was smallest, followed by the largest
observed increase in uorescence intensity (38.2  0.9% aer
55 min.). The observed concentration-dependent decrease/
increase pattern suggest a rearrangement of nanosponge
structure during caspase-6 digestion. This hypothesis is
corroborated by TEM results, which are shown in Fig. 5. As
shown in Fig. 4A, the amount of released carboxyuorescein is
clearly dependent on the concentration of caspase-6 that was
added. The use of PBS medium ensured that the pH of all
systems was 7.4. However, due to the observed rearrangement
of the nanosponge structure aer enzymatic cleavage, the
amount of released uorescent dye is not a linear function of
the observed uorescent increase. Nevertheless, the experi-
mental data summarized in Fig. 4 clearly demonstrates the
potential of DK20 nanosponges for cell-based drug delivery. It
should be noted that DK20 nanosponges in PBS containing 5
percent (by volume) of human serum were stable for 24 h,
indicating virtually no proteolytic cleavage. This result is
important, because it demonstrated that DK20 nanosponges
are at least short-term stable in the presence of serum, due to
the absence of active caspases. This is of importance for the
uptake experiments of type DK20 nanosponges by leucocytes in
peripheral blood discussed below. At higher concentrations of
serum in PBS, DLS could not be utilized as a detection method
due to the presence of thousands of human proteins.TEM-analysis of caspase-6 activation
Bright eld TEM was also successfully used to visualize the
eﬀect of caspase-6 activation of carboxyuorescein-loaded DK20
nanosponges. In Fig. 5, a sequence of three TEM images is
shown: (A) 0.20 mg mL1 of CF-DK20 nanosponges, deposited
from PBS dispersion onto HOPG. (B) 0.20 mg mL1 of CF-DK20
nanosponges aer 15 min. Of incubation at 37 C with
commercially available caspase-6 (2.60  1010 M), deposited
from PBS dispersion onto HOPG. (C) 0.20 mg mL1 of CF-DK20
nanosponges aer 60 min. Of incubation at 37 C with
commercially available caspase-6 (2.60  1010 M), deposited
from PBS dispersion onto HOPG. TEM images were recorded
immediately aer the deposition of the (reactive) nanosponges
on the carbon surfaces. Uranyl staining was added shortly
before depositing the dispersions onto HOPG.
Fig. 5 shows that caspase-digestion of CF-DK20 nanosponges
leads to the formation of a novel supramolecular structure. We
have observed that the presence of a charged molecule (here:
5(6)-carboxyuorescein) within the DK20 framework will inu-
ence the size of the formed aggregates. This eﬀect is responsible
for the diﬀerences in diameter that are observed compared to
the TEM shown in Fig. 3 and ref. 38. Furthermore, the spherical
nanosponges are deposited onto a carbon surface for the
purpose of TEM. This will atten their structures to a 2D coating
and, at least partially, lead to the orientation of the hydrophobic
cholesterol labels towards the carbon surface. Therefore, in
contrast to dynamic light scattering, the nanosponges' structure
will be somewhat distorted by the procedures necessary to
record TEM. The resulting nanosponge diameters were 45 
10 nm (Fig. 6).This journal is © The Royal Society of Chemistry 2018
Fig. 6 Size distribution of carboxyﬂuorescein-loaded DK20 nano-
sponges before and after “digestion” with caspase-6 (as measured by
means of TEM, n: number of particles counted).
Fig. 7 Cell viability of C17.2 neural progenitor cells (NPCs) as a func-
tion of DK20 nanosponge concentration and incubation time (24 h
and 48 h), as measured by the MTT assay.45 Nanosponges were added
to the cell culture medium in their respective concentrations (see
ESI†). The cell viabilities after 24 h and 48 h in the absence of DK20
nanosponge, shown at 0 mM of DK20 nanosponges, were used as
references to calculate viabilities.
Fig. 8 Uptake eﬃcacy of type DK20 nanosponges by non-gran-
ulocyte leukocytes (mainly lymphocytes and monocytes) and gran-
ulocytes (neutrophils) in peripheral blood as function of incubation
time.
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View Article OnlineIn Fig. 5B the originally observed organic structures have
completely vanished and a mesh of organic structures has
formed. It is our interpretation of this observation that caspase-
6 was able to cleave at least a fraction of the DEVDGC, thus
disrupting the structure of the nanosponges. Enzymatic
cleavage releases cholesterol-K20-DE and cholesterol-D20-DE
units, and according to the results shown in Fig. 5c, these units
(or at least cholesterol-K20-DE) are able to form novel supra-
molecular structures. The re-formation of well-ordered struc-
tures may be responsible for the observed release of “only”Table 1 Uptake of DK20 nanosponges by leukocytes in peripheral bloo
DK20 Nanosponges
30 min 3 h
Neutrophils
loaded
Other leukocytes
loaded
Neutrophil
loaded
Ave-rage 4.3% 22.6% 19.5%
StDev 2.4% 6.0% 5.4%
This journal is © The Royal Society of Chemistry 2018about 3.7  0.1% of carboxyuorescein, which was observed by
means of quantitative uorescence recording. Interestingly, the
supramolecular structures formed aer 1 h of “digestion” with
caspase-6 (2.60  1010 M) are larger than the original nano-
sponges (110  20 nm, Fig. 6).Cell toxicity of the peptide nanosponges
We have performed classic MTT cell proliferation assays45 to
determine the cell viability of murine C17.2 neural progenitor
cells (NPCs)34 aer incubation with DK20 nanosponges. DK20
nanosponges are not toxic to NPCs, even at concentrations as
large as 100 mM (Fig. 7). Only a slight increase in cell prolifer-
ation was observed at lower concentrations.Nanosponge-uptake by leucocytes in peripheral blood
Cell uptake kinetics were recorded to determine the uptake
eﬃciencies of the peptide nanosponges by neutrophils and
leukocytes in peripheral blood. The results are summarized in
Table 1 and Fig. 8. They indicate that the targeting of defensive
cells within peripheral blood, followed by cell-based transport
to the tumor site, is a feasible treatment strategy.
White blood cells from cattle blood show a time dependent
uptake of DK20 nanosponges. The entire WBC (white blood
cells) population was subclassied into granulocytes (neutro-
phils) and other leukocytes such as lymphocytes and mono-
cytes. Here, the other leukocyte group loaded twice as well
(>50%) compared to the granulocyte group (25%). The loading
was observed over a timeframe of 6 hours with the maximum
loading completed aer 3 hours.d
6 h
s Other leukocytes
loaded
Neutrophils
loaded
Other leukocytes
loaded
49.4% 25.0% 54.0%
14.8% 17.3% 19.7%
RSC Adv., 2018, 8, 16052–16060 | 16057
Fig. 9 Survival of WBC when exposed to DK20 peptide nanosponges,
compared to the survival of an unexposed WBC control group. No
signiﬁcant diﬀerence (p > 0.05) between the treated and untreated live
cell populations was detected.
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View Article OnlineSurvival of the WBC population was analyzed by detecting
apoptotic cells with the annexin V uorescent marker and dead
cells with propidium iodine. The relative survival was measured
aer 5.5 and 7 hours of incubation with DK20 nanosponges and
compared to a control group. The live cell population remained
between 78% and 89% relative to the total cell count and with
no signicant diﬀerence between the control and the DK20
group for the duration of the experiment. Apoptotic cells were at
approximately 12% aer 5.5 hours, again with no signicant
diﬀerence between the two groups. The apoptotic cell count in
the DK20 nanosponge group drops to 2% aer seven hours
while the dead cell count is signicantly increased and
measured at 15%. Our hypothesis is that this is observed due to
the stress exerted on the WBS from endocytosis and processing
of the DK20 nanosponges (Fig. 9).Discussion
Three main obstacles to eﬃcient cell-mediated therapy of
cancer and infectious diseases remain today: (1) fast uptake of
drug formulations by the transport cells. (2) Eﬀective migration
of the transport cells to their intended target. (3) Eﬃcient drug
release by the transport cells once the target is reached. The
nanosponges that are discussed here will be able to eﬃciently
target neural progenitor cells38,53 and leucocytes, either ex vivo
or, preferentially, in peripheral blood to utilize the advantages
of autologous cells for patient-specic cell therapies. Because of
their fast uptake kinetics, and virtually non-existent toxicity, the
nanosponges are well-suited for loading numerous drug
formulations into various types of transport cells. Furthermore,
because of their low toxicity to the transport cells, they make
a very important contribution to facilitating eﬀective cell
migration to targets in vivo, because the viability of the transport
cells will remain high during the migration phase of several
days. In our previous work, we have observed by means of
uorescence microscopy that type DK20 nanosponges retained
their structures within the cytoplasm of monocyte/macrophage-
like cells (RAW 264.7) for up to 72 h (ref. 38). Since RAW 264.7
cells belong to the group of leukocytes, this nding has
importance for the study reported here. Finally, as we have
demonstrated here by utilizing 5(6)-carboxyuorescein as16058 | RSC Adv., 2018, 8, 16052–16060model drug, caspase-mediated drug release can be achieved.
The observed increase in carboxyuorescein emission was 38.2
 0.9% aer 55 min in the presence of 1.0  106 M of caspase-
6 in PBS, compared to PBS alone. Furthermore, the “caspase
storm” during apoptosis has the potential of further degrading
the nanosponges and to create numerous apoptotic bodies, to
which the nanosponge-derived components will be adsorbed.
Therefore, we anticipate a very high degree of drug release and
consequent re-uptake in vivo.
We have utilized caspase-6 (MEROPS, ID: C14.005) in our
studies, because it is one of the “eﬀector caspases of
apoptosis”.54 Caspases 3 and 6 are responsible for signicant
morphological changes in the nucleus at the onset of apoptosis.
Caspase-6 cleaves nuclear lamina and the protein NuMa of the
nuclear mitotic apparatus. Caspase-6 is also a suitable protease
to cleave the DEVDGC motif of the nanosponges. According to
this mechanism, drug release from the nanosponges within the
transport cells can be triggered by apoptosis.55 It is noteworthy
that the consensus sequence DEVGDC is also capable of react-
ing with the other eﬀector caspases-2, -3, and -7.39
Neutrophils make up a signicant percentage of leucocytes.56
As already discussed, neutrophils undergo apoptosis within
hours aer reaching tumors andmetastases.56 This makes them
very attractive autologous cells for tumor targeting. Neural
progenitor cells constitute a second class of delivery cells, which
can migrate to solid tumors and metastases in large
numbers.29,34,46 However, the release of the payload has to be
triggered by introducing apoptosis, as described above of by
designing a TetOn gene regulation system, which silences
a specic gene unless a tetracycline, such as doxycycline, is
present.10,57Conclusion
The structure predictions for the supramolecular binary nano-
sponges (type DK20) through explicit solvent and then coarse-
grained molecular dynamics (MD) simulations, have been
conrmed by transmission electron microscopy and dynamic
light scattering studies. The structural and dynamic under-
standing of the nanosponges has enabled several applications
of these novel materials, which, principally, prove them as
advanced biomaterials in cell-mediated drug transport to solid
tumors/metastases and infectious diseases: caspase-activated
(model) drug release was demonstrated with 5(6)-
carboxyuorescein-loaded nanosponges. PKH26-loaded nano-
sponges were essentially non-toxic to cultured neural progenitor
cells (NPC).38 Targeting of leucocytes (WBC) in peripheral blood
was successful. Aer 3 h of incubation, maximal uptake into
non-granulocytic leukocytes and granulocytes in peripheral
blood was observed. No signicant diﬀerence between the
untreated and DK20-nanosponge-treated live cell populations
was detected. These results indicate that leucocytes in periph-
eral blood can be targeted by DK20 nanosponges without the
requirement of previous isolation. We regard this as an
important step towards cell-mediated therapy of tumors
utilizing autologous cells as delivery vectors.This journal is © The Royal Society of Chemistry 2018
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